Rudra Investment Technical And Derivative Report(23rd April)
Sun Pharmaceutical Industries' one of the wholly owned subsidiaries has increased its shareholding in Ranbaxy Malaysia, Malaysia, by way of further purchase of 394,404 shares of face value of MYR 1.00 each (equivalent to 4.93%) of Ranbaxy Malaysia. Ranbaxy Malaysia is a subsidiary of the company, and the total shareholding of Sun Pharmaceutical Industries, along with its wholly owned subsidiary is 90.74%, prior to this purchase of shares. the total holding of the company along with its wholly owned subsidiary will increase from 90.74% to 95.67% in Ranbaxy Malaysia.
★
★
★
★
★
102 views • 7 slides
